Nektar Therapeutics - Common Stock (NKTR)
44.49
+0.55 (1.25%)
NASDAQ · Last Trade: Dec 28th, 5:53 PM EST
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.
Via The Motley Fool · December 28, 2025
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.
Via The Motley Fool · December 28, 2025
Shares in the biotech company have surged on news of a big pharma takeover.
Via The Motley Fool · November 20, 2025
Nektar Therapeutics (NKTR) Q3 2025 results beat analyst estimates for both revenue and earnings per share, sending the stock higher in after-hours trading.
Via Chartmill · November 6, 2025
Is it too late to get on the bandwagon?
Via The Motley Fool · October 13, 2025
Results of the Resolve-AD trial with rezpegaldesleukin were better than expected.
Via The Motley Fool · October 5, 2025
Here's what needs to happen for these high flyers to continue soaring.
Via The Motley Fool · September 21, 2025
One of the company's pipeline drugs is showing significant promise.
Via The Motley Fool · September 18, 2025
Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.
Via Benzinga · September 18, 2025
The company's competitive positioning might be stronger now, after disappointing results from a key rival.
Via The Motley Fool · September 5, 2025
Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.
Via Benzinga · September 4, 2025
Via Benzinga · September 4, 2025
Via Benzinga · September 4, 2025
The company said it has sufficient financial resources to fund its operations into early 2027.
Via The Motley Fool · August 8, 2025
These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies
Via MarketBeat · July 21, 2025
U.S. futures slipped on Tuesday after two days of record-setting advances. Futures of major benchmark indices were trading lower.
Via Benzinga · July 1, 2025
Via Benzinga · July 1, 2025
With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?
Via MarketBeat · June 30, 2025
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.
Via MarketBeat · June 28, 2025
The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis.
Via Stocktwits · June 25, 2025